U.S. Markets open in 3 hrs 17 mins
  • Crude Oil

    70.51
    -0.05 (-0.07%)
     
  • Gold

    1,776.10
    -2.10 (-0.12%)
     
  • Silver

    22.53
    -0.04 (-0.17%)
     
  • EUR/USD

    1.1733
    +0.0003 (+0.0235%)
     
  • 10-Yr Bond

    1.3240
    0.0000 (0.00%)
     
  • Vix

    22.94
    -2.77 (-10.77%)
     
  • GBP/USD

    1.3635
    -0.0030 (-0.2168%)
     
  • USD/JPY

    109.5300
    +0.3100 (+0.2838%)
     
  • BTC-USD

    44,590.88
    -3,435.44 (-7.15%)
     
  • CMC Crypto 200

    1,057.10
    -6.75 (-0.63%)
     
  • FTSE 100

    7,060.31
    +79.33 (+1.14%)
     
  • Nikkei 225

    29,639.40
    -200.31 (-0.67%)
     

Here's Why You Should Retain Stryker (SYK) Stock Right Now

  • Oops!
    Something went wrong.
    Please try again later.
·4 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Stryker Corporation SYK is well poised for growth backed by robust robotic-arm assisted surgery platform — Mako and diversified product portfolio. However, pricing pressure remains a headwind.

Shares of the company have gained 43.5% compared with the industry’s 23.3% rally on a year-to-date basis. Meanwhile, the S&P 500 Index has surged 56% in the same time frame.

Stryker, with a market capitalization of $96.62 billion, is one of the world’s largest medical device companies operating in the orthopedic market. It anticipates earnings to improve 9.6% in the next five years. Moreover, it has a trailing four-quarter earnings surprise of 18.8%, on average.


Let’s take a closer look at the factors that substantiate the company’s Zacks Rank #3 (Hold).

What’s Deterring the Stock?

An unfavorable pricing environment poses a persistent threat to Stryker’s core businesses. In fact, pricing in fourth-quarter 2020 had an impact of 0.8% on the top line. Hence, pricing pressure continues to weigh on its performance.

What’s Favoring Growth?

Mako is Stryker’s robotic-arm assisted surgery platform. The company continues to witness strong demand for Mako and healthy order book, courtesy of the platform’s unique features, despite financial constraints stemming from the COVID-19 pandemic. This, in turn, positions it well to sustain momentum in robot sales and recon share market gains. For 2021, the company’s Mako order book remains solid, and is in sync with its aim of continuous share gains in both hips and knees.

During 2020, the company’s Mako install base saw 33% growth, and beat another milestone with more than 100 robots sold and installed in fourth-quarter 2020. Thereby, it continues to focus on the expansion of Mako.

Additionally, Stryker has a diversified product portfolio. Its wide range of products shields the company against any significant sales shortfall during economic turmoil. Its significant exposure in robotics, Artificial Intelligence for health care and Medical Mechatronics has provided the company with a competitive edge in the MedTech space. Stryker’s portfolio includes products like Hip, Knee and Mako robotic-arm assisted surgeries.

During fourth-quarter 2020, the company unveiled the ASC (Ambulatory Surgery Center) sales model that leverages its portfolio by offering end-to-end solutions to cater to the rising demand and shifts regarding outpatient setting. Per management, the company’s sustained support for customers and focus on innovation will position it well for growth, as the pandemic eventually subsides.

Apart from these, Stryker has been one of the earliest adopters of the 3D printing technology. The company’s FDA-approved Tritanium TL Curved Posterior Lumbar Cage is a 3D-printed interbody fusion cage intended for use as an aid in lumbar fixation.

Estimates Trend

For 2021, the Zacks Consensus Estimate for revenues is pegged at $17.07 billion, indicating an improvement of 18.9% from the previous year. The same for earnings stands at $9.05, suggesting growth of 21.8% from the year-ago reported figure.

Stocks to Consider

Some better-ranked stocks from the broader medical space include AmerisourceBergen Corporation ABC, DENTSPLY SIRONA Inc. XRAY and Cantel Medical Corp. CMD, each currently carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

AmerisourceBergen’s long-term earnings growth rate is expected at 11.4%.

DENTSPLY SIRONA’s long-term earnings growth rate is estimated at 20%.

Cantel Medical’s long-term earnings growth rate is estimated at 19%.

+1,500% Growth: One of 2021’s Most Exciting Investment Opportunities

In addition to the stocks you read about above, would you like to see Zacks’ top picks to capitalize on the Internet of Things (IoT)? It is one of the fastest-growing technologies in history, with an estimated 77 billion devices to be connected by 2025. That works out to 127 new devices per second.

Zacks has released a special report to help you capitalize on the Internet of Things’s exponential growth. It reveals 4 under-the-radar stocks that could be some of the most profitable holdings in your portfolio in 2021 and beyond.

Click here to download this report FREE >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Stryker Corporation (SYK) : Free Stock Analysis Report

DENTSPLY SIRONA Inc. (XRAY) : Free Stock Analysis Report

AmerisourceBergen Corporation (ABC) : Free Stock Analysis Report

Cantel Medical Corp. (CMD) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research